AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05945056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy(Transcutaneous Electrical Nerve Stimulator)
Description: TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
Study NCT05945056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy(Transcutaneous Electrical Nerve Stimulator)
Description: TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
Study NCT05945056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
Study NCT03454516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telemonitoring
Description: the follow-up of the patient will be performed with Telemonitoring
Study NCT04066569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam
Description: After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions
Study NCT04066569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)
Description: After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo.
Study NCT02684656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: Hemodiafiltration >/=4h, > 20l convection
Study NCT03000543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Study NCT03887065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-4
Description: Novel small human peptide derived from erythropoietin
Study NCT03943680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRGF
Description: After tooth extraction, the socket will be grafted with PRGF-Endoret
Study NCT03943680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABB
Description: After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
Study NCT01382004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin-G-benzathine
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Study NCT01382004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Study NCT02574013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoractor®
Description: Endoscopic sponge for retraction of small intestine
Study NCT03398057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo health education (pamphlets) will be applied to this group participants during study.
Study NCT03096379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enterography performed via magnetic resonance imaging
Study NCT04070105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
Study NCT04238286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
Study NCT04238286 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling
Description: All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
Study NCT04070105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running
Study NCT03064256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training program
Description: Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
Study NCT03064256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training program
Description: All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
Study NCT05989789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radioactive Seed Implantation
Description: In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
Study NCT00723515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride
Description: sodium fluoride 5%
Study NCT00723515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride calcium fluoride
Description: sodium fluoride 5% + calcium fluoride
Study NCT02666118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive Interscalene Block - Single Shot
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
Study NCT02666118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Interscalene Block- Single Shot
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
Study NCT02666118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive Interscalene Block - Catheter
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
Study NCT02666118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Interscalene Block - Catheter
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
Study NCT00517634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD
Study NCT00517634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Study NCT00517634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT02438670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PID control algorithm
Study NCT02438670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC control algorithm
Study NCT04026256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: teriparatide daily subcutaneous injection
Study NCT00737152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAS 130 with diet and exercise
Description: Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
Study NCT04102553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18-PSMA-1007
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study NCT04102553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-PSMA-1007
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study NCT04102553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18-Fluorocholine
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study NCT03502044 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes inactive KOS treatment in each nasal cavity.
Study NCT03502044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes active KOS treatment in each nasal cavity.
Study NCT03502044 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes active KOS treatment in each nasal cavity.
Study NCT04102553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-Fluorocholine
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study NCT01512680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education to Functional Insulin Therapy
Description: * Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary
Study NCT03497091 — intervention group
Intervention type: OTHER
Intervention: Enteral Formula
Description: Enteral Feeding with an amino acid-based formula
Study NCT03705780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the short OSAS scale
Description: Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
Study NCT03705780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fentanyl test
Description: In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
Study NCT01352624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: $AFE
Description: $teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
Study NCT02944305 — intervention group
Intervention type: PROCEDURE
Intervention: Endotracheal intubation
Description: Endotracheal intubation under direct laryngoscopy using McIntosh blade
Study NCT04026256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: denosumab subcutaneous injection
Study NCT00534677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: 2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
Study NCT01963013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-returning catheter valve
Study NCT01963013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional urine bag
Study NCT03221608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and HIPEC with Lobaplatin
Description: The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
Study NCT03221608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without HIPEC
Description: The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
Study NCT00266929 — intervention group
Intervention type: PROCEDURE
Intervention: surgical
Description: surgical treatment of odontoid fractures
Study NCT00534677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
Study NCT00266929 — intervention group
Intervention type: PROCEDURE
Intervention: conservative treatment
Description: conservative stabilization of fractures
Study NCT00098722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Study NCT00098722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized background therapy
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]
Study NCT00098722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken twice daily
Study NCT01051024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
Study NCT01051024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
Study NCT00812370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
Study NCT03896776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up! 3.0
Description: KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
Study NCT01108705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
Study NCT01108705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, once daily, until disease progression or toxicity
Study NCT02862613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
Study NCT02862613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
Study NCT02862613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT00098722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: optimized background therapy
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]